The implementation of a field-based medical service (usually a medical science liaison [MSL] team) is widely regarded as a must-have in the early stages of product launch readiness.

As pharmaceutical companies navigate an increasingly complex landscape, the Medical Affairs function has evolved from a purely supportive role into a strategic powerhouse that drives product success across the lifecycle.

Never underestimate it - successfully launching a new medicine into major European markets is a complex and highly fragmented process that requires deep strategic planning and flawless execution.

As the bridge between scientific innovation and clinical application, the role of Medical Affairs (at least as it's intended) is multifaceted and dynamic, involving medical strategy, external stakeholder engagement, internal collaboration, creation of new data and the dissemination of scientific knowledge.

The implementation of a field‑based medical service (usually a medical science liaison [MSL] team) is widely regarded as a must‑have in the early stages of product launch readiness – whether to support the delivery of Phase 3 clinical trials, initiate early external engagement with potential future prescribers and key opinion leaders (KOLs), or begin Medical Affairs initiatives.